Ralinepag is an oral, once-daily, selective prostacyclin IP receptor agonist developed to treat pulmonary arterial hypertension (PAH).
A new trial evaluated the efficacy and safety of ralinepag in patients with PAH: spkl.io/60117z4iF
Ralinepag is an oral, once-daily, selective prostacyclin IP receptor agonist developed to treat pulmonary arterial hypertension (PAH).
A new trial evaluated the efficacy and safety of ralinepag in patients with PAH: spkl.io/60117z4iF